Norton Cancer Institute has administered the first dose of OncoC4 Inc.'s novel SIGLEC10 inhibitor, ONC-841, to a patient with advanced solid tumors in a Phase 1 clinical trial (NCT06352359). This marks a significant step in evaluating a new approach to cancer treatment. The trial, led by principal investigator Tianhong Li, M.D., Ph.D., of the University of California, Davis Comprehensive Cancer Center, aims to assess the safety, side effects, and optimal dosing of ONC-841 in patients with advanced or metastatic solid tumors.
ONC-841: Targeting SIGLEC10
ONC-841 is a first-in-class immune checkpoint inhibitor targeting SIGLEC10, a protein that suppresses the immune system's ability to attack cancer cells. By blocking SIGLEC10, ONC-841 aims to enhance the anti-tumor immune response, potentially leading to tumor shrinkage and slower disease progression. The drug is administered via IV infusion.
Phase 1 Trial Details
The Phase 1 trial is designed to evaluate the safety, tolerability, and preliminary efficacy of ONC-841 in patients with various types of advanced solid tumors that have spread beyond the primary site. Key objectives include determining the recommended Phase 2 dose and assessing the drug's impact on tumor size and disease progression. According to Dr. John T. Hamm, the site investigator from Norton Cancer Institute, clinical trials like this have led to rapid improvements in cancer care and treatment over the past five years.
Norton's Role in Cancer Research
Norton Research Institute is actively involved in numerous research studies, with approximately 750 ongoing investigations across multiple medical specialties. More than 100 of these studies are cancer-specific clinical trials, including 34 Phase 1 trials focused on evaluating the safety and dosing of new treatments.
